-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Surgery Partners, Lowers Price Target to $30

Benzinga·11/11/2025 13:37:01
Listen to the news
Benchmark analyst Bill Sutherland maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $35 to $30.